Pfizer Thailand
Pfizer Thailand is the Thai subsidiary of Pfizer Inc. (US-parent global pharmaceutical group). Thailand operation is among the top MNC originator subsidiaries by Thai market share (~7% by value). Therapeutic focus: oncology (Ibrance, Xtandi, Braftovi, Mektovi, Bavencio), primary care (Lipitor off-patent, specialty cardiovascular), vaccines (Prevenar 20, Comirnaty COVID, Abrysvo RSV, Nimenrix meningitis), rare disease (Vyndaqel, BeneFIX). Not listed in Thailand; consolidated into Pfizer Inc. parent.
Snapshot
Headline numbers a buyer checks first.
Thai market share
~7% by value
FY2024
Parent
Pfizer Inc. (NYSE: PFE)
Subsidiary since 1957
Focus areas
Oncology, primary care, vaccines, rare disease
FY2024
Status
Private Thai subsidiary
Ongoing
What this subsidiary actually does
Pfizer Thailand imports, markets, and distributes Pfizer Inc.-originated pharmaceutical products in Thailand. Oncology franchise is a priority: Ibrance (palbociclib, breast cancer), Xtandi (enzalutamide, prostate cancer), Braftovi, Mektovi (melanoma, colorectal combinations), Bavencio (avelumab, urothelial, other cancers). Primary care, cardiovascular: Lipitor generic-era portfolio, Vyndaqel (ATTR amyloidosis specialty). Vaccine portfolio: Prevenar 20 pneumococcal, Comirnaty COVID-19, Abrysvo RSV, Nimenrix meningococcal. Channels: MoPH central procurement, hospital direct, retail-pharmacy.[]
Strategic position: Pfizer is a top-3 MNC originator in Thailand via oncology, specialty portfolio breadth. Post-COVID revenue normalised as Comirnaty, Paxlovid demand compressed; oncology, primary care, new vaccine launches drive 2024-2026 trajectory. Competitive set: Roche, Novartis, Merck KGaA, AstraZeneca in oncology; GSK, Sanofi, Merck in vaccines. Patent-expiry, biosimilar pressure on mature products continues; new-product-pipeline execution is the medium-term variable.[, ]
Business segments
Oncology
Ibrance, Xtandi, Bavencio
Palbociclib breast cancer, enzalutamide prostate cancer, avelumab urothelial; priority growth franchise accounting for ~45% of Thai Pfizer revenue in FY2024.
Vaccines
Prevenar 20, Comirnaty, Abrysvo
Pneumococcal 20-valent, COVID-19 mRNA, RSV adult vaccine; MoPH central procurement and private-clinic channels. Estimated 2-3 million doses annually in Thailand.
Primary care
Cardiovascular, rare disease
Lipitor off-patent portfolio, Vyndaqel ATTR amyloidosis, BeneFIX haemophilia; lower-growth but established hospital-channel revenues.
Channels
MoPH, hospital, retail
Mix of central MoPH procurement tenders, hospital formulary direct, and private-pharmacy retail. Government tender pricing applies to UCS high-cost-drug list.
MNC originator peer comparison β Thai market
Indicative FY2024 estimates; values in USD millions unless stated
Thai mkt share
~7%
Therapeutic focus
Oncology, vaccines, rare disease
Parent listing
NYSE: PFE
Thai mkt share
~9%
Therapeutic focus
Oncology, diagnostics
Parent listing
SIX: ROG
Thai mkt share
~5%
Therapeutic focus
Specialty, biosimilars
Parent listing
NYSE: NVS
AstraZeneca Thailand
Thai mkt share
~6%
Therapeutic focus
Oncology, respiratory, cardiovascular
Parent listing
LSE: AZN
| Entity | Thai mkt share | Therapeutic focus | Parent listing |
|---|---|---|---|
| Pfizer Thailand | ~7% | Oncology, vaccines, rare disease | NYSE: PFE |
| Roche Thailand | ~9% | Oncology, diagnostics | SIX: ROG |
| Novartis Thailand | ~5% | Specialty, biosimilars | NYSE: NVS |
| AstraZeneca Thailand | ~6% | Oncology, respiratory, cardiovascular | LSE: AZN |
| GSK Thailand | ~4% | Vaccines, respiratory, HIV | LSE: GSK |
Watchpoints 2025-2026
Growth
Oncology NLEM inclusion
Ibrance, Xtandi NLEM listing or UCS high-cost-drug access expansion is the highest-impact near-term revenue lever. Each inclusion adds MoPH-tender volume at scale.
Risk
Post-COVID revenue normalisation
Comirnaty, Paxlovid volumes compressed from 2022 peak. Vaccine revenue dependent on seasonal booster programme continuation and MoPH annual procurement decisions.
Structural
Biosimilar substitution timeline
Patent-expiry on mature branded products (Lipitor analogues, older biologics) invites biosimilar competition; pace of substitution in Thai hospital formularies is the key variable.
Watchpoints
Oncology franchise, NLEM/UCS
Ibrance, Xtandi, novel-therapy wins; NLEM inclusion, UCS high-cost-drug access.
Vaccine portfolio post-COVID
Prevenar 20, Abrysvo RSV, paediatric launches vs COVID-revenue normalisation.
Biosimilar pressure
Mature-product patent-expiry, biosimilar substitution timeline.
Parent pipeline execution
Pfizer Inc. global R&D productivity, Thai launch timing.
Related Market profiles
Peers, parents, partners, agencies, and other Pharmaceuticals actors.
Competitor
GSK Thailand
MNC originator peer; GSK respiratory, vaccines; Pfizer oncology, primary care.
Open Market profile β
Competitor
Roche Thailand
Specialty oncology, biologics peer.
Open Market profile β
Competitor
Novartis Thailand
Specialty, oncology, biosimilar peer.
Open Market profile β
Sector peer
Government Pharmaceutical Organisation (GPO)
Thai state pharmaceutical manufacturer; generics, HIV ARV, biosimilar, Strategic Stockpile; FY2024 revenue ~ $463.8M.
Open Market profile β
Sources + data provenance
Every filing, filing-adjacent register, or trusted industry source cited in this profile.
Pfizer Thailand β Subsidiary Disclosures
National List of Essential Medicines (NLEM) β Committee, Pricing
Publisher
Ministry of Public Health, Drug Subcommittee
Grade
Primary
As of
2025-12-31
| Source | Publisher | Grade | As of |
|---|---|---|---|
| Pfizer Thailand β Subsidiary Disclosures | Pfizer Thailand (MNC subsidiary) | Well established | 2025-12-31 |
| National List of Essential Medicines (NLEM) β Committee, Pricing | Ministry of Public Health, Drug Subcommittee | Primary | 2025-12-31 |
Reports featuring this profile
Thailand Pharmaceuticals Market Intelligence
US-parent MNC originator subsidiary; oncology, primary care, vaccines, rare disease; ~7% Thai market share by value.
Open report β
Sits alongside 7 other Atlas profilesThailand Pharma Generic vs Branded Deep Dive
Pfizer Thailand branded innovator MNC.
Open report β
Sits alongside 7 other Atlas profilesRelated Market profiles
competitor
GSK Thailand
UK-parent MNC originator Thai subsidiary; respiratory, vaccines, HIV, oncology; ~8% Thai market value share.
competitor
Roche Thailand
Swiss-parent MNC specialty Thai subsidiary; oncology, biologics, diagnostics; ~5% Thai market value share.
competitor
Novartis Thailand
Swiss-parent MNC specialty Thai subsidiary; oncology, cardiovascular, biosimilar; ~6% Thai market value share.